×
S&P 500   3,891.27 (+1.20%)
DOW   31,295.72 (+0.83%)
QQQ   293.87 (+1.76%)
AAPL   145.82 (+2.03%)
MSFT   267.53 (+0.50%)
META   171.24 (+0.87%)
GOOGL   2,353.60 (+2.71%)
AMZN   116.20 (+1.64%)
TSLA   728.16 (+4.74%)
NVDA   157.80 (+4.30%)
NIO   22.36 (+7.35%)
BABA   123.87 (+3.99%)
AMD   79.10 (+4.98%)
MU   58.49 (+1.95%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.40 (+1.35%)
F   11.60 (+4.88%)
DIS   97.06 (+1.02%)
AMC   13.95 (+10.98%)
PFE   53.16 (+0.78%)
PYPL   74.43 (+1.62%)
NFLX   188.85 (+2.60%)
S&P 500   3,891.27 (+1.20%)
DOW   31,295.72 (+0.83%)
QQQ   293.87 (+1.76%)
AAPL   145.82 (+2.03%)
MSFT   267.53 (+0.50%)
META   171.24 (+0.87%)
GOOGL   2,353.60 (+2.71%)
AMZN   116.20 (+1.64%)
TSLA   728.16 (+4.74%)
NVDA   157.80 (+4.30%)
NIO   22.36 (+7.35%)
BABA   123.87 (+3.99%)
AMD   79.10 (+4.98%)
MU   58.49 (+1.95%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.40 (+1.35%)
F   11.60 (+4.88%)
DIS   97.06 (+1.02%)
AMC   13.95 (+10.98%)
PFE   53.16 (+0.78%)
PYPL   74.43 (+1.62%)
NFLX   188.85 (+2.60%)
S&P 500   3,891.27 (+1.20%)
DOW   31,295.72 (+0.83%)
QQQ   293.87 (+1.76%)
AAPL   145.82 (+2.03%)
MSFT   267.53 (+0.50%)
META   171.24 (+0.87%)
GOOGL   2,353.60 (+2.71%)
AMZN   116.20 (+1.64%)
TSLA   728.16 (+4.74%)
NVDA   157.80 (+4.30%)
NIO   22.36 (+7.35%)
BABA   123.87 (+3.99%)
AMD   79.10 (+4.98%)
MU   58.49 (+1.95%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.40 (+1.35%)
F   11.60 (+4.88%)
DIS   97.06 (+1.02%)
AMC   13.95 (+10.98%)
PFE   53.16 (+0.78%)
PYPL   74.43 (+1.62%)
NFLX   188.85 (+2.60%)
S&P 500   3,891.27 (+1.20%)
DOW   31,295.72 (+0.83%)
QQQ   293.87 (+1.76%)
AAPL   145.82 (+2.03%)
MSFT   267.53 (+0.50%)
META   171.24 (+0.87%)
GOOGL   2,353.60 (+2.71%)
AMZN   116.20 (+1.64%)
TSLA   728.16 (+4.74%)
NVDA   157.80 (+4.30%)
NIO   22.36 (+7.35%)
BABA   123.87 (+3.99%)
AMD   79.10 (+4.98%)
MU   58.49 (+1.95%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.40 (+1.35%)
F   11.60 (+4.88%)
DIS   97.06 (+1.02%)
AMC   13.95 (+10.98%)
PFE   53.16 (+0.78%)
PYPL   74.43 (+1.62%)
NFLX   188.85 (+2.60%)
NASDAQ:IRIX

IRIDEX Stock Forecast, Price & News

$2.60
-0.06 (-2.26%)
(As of 07/7/2022 10:17 AM ET)
Add
Compare
Today's Range
$2.60
$2.60
50-Day Range
$2.47
$3.86
52-Week Range
$2.45
$9.46
Volume
100 shs
Average Volume
49,392 shs
Market Capitalization
$41.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IRIDEX MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$6,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.51) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.56 out of 5 stars

Computer And Technology Sector

835th out of 936 stocks

Electromedical Equipment Industry

29th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

IRIDEX logo

About IRIDEX (NASDAQ:IRIX) Stock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Stock News Headlines

StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)
Investors Look to Capitalize on the Budding Green Revolution
Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Aqua Metals Announces Q1 2022 Results - Yahoo Finance
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
119
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/07/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-5,220,000.00
Pretax Margin
-10.04%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$1.47 per share

Miscellaneous

Free Float
15,442,000
Market Cap
$41.31 million
Optionable
Not Optionable
Beta
1.27














IRIDEX Frequently Asked Questions

How has IRIDEX's stock performed in 2022?

IRIDEX's stock was trading at $6.11 at the start of the year. Since then, IRIX shares have decreased by 57.4% and is now trading at $2.60.
View the best growth stocks for 2022 here
.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for IRIDEX
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Thursday, May, 12th. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The medical equipment provider had revenue of $13.39 million for the quarter, compared to analysts' expectations of $13.40 million. IRIDEX had a negative net margin of 10.13% and a negative trailing twelve-month return on equity of 35.55%.
View IRIDEX's earnings history
.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX updated its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $57.00 million-$59.00 million, compared to the consensus revenue estimate of $58.49 million.

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:
  • Mr. David I. Bruce, Pres, CEO & Director (Age 63, Pay $701.07k)
  • Mr. Fuad Ahmad, Interim Chief Financial Officer (Age 52, Pay $560.4k)
  • Mr. Patrick Mercer, Chief Operating Officer (Age 50, Pay $516.02k)
  • Ms. Leigh Salvo, Head of Investor Relations

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX CEO Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among IRIDEX's employees.

What other stocks do shareholders of IRIDEX own?

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.60.

How much money does IRIDEX make?

IRIDEX (NASDAQ:IRIX) has a market capitalization of $41.31 million and generates $53.90 million in revenue each year. The medical equipment provider earns $-5,220,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does IRIDEX have?

IRIDEX employs 119 workers across the globe.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for IRIDEX is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.

This page (NASDAQ:IRIX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.